Shift Pharmaceuticals, Charcot-Marie-Tooth Association Partner on ASO Treatment for CMT1A
GLENOLDEN, PA, USA, November 3, 2022 /EINPresswire.com/ -- Shift Pharmaceuticals, a privately held company that is developing antisense oligonucleotides (ASOs) to treat a variety of genetic disorders, and the Charcot-Marie-Tooth Association (CMTA) …